This activity is provided by Creative Educational Concepts.
This activity is supported by an educational grant from AstraZeneca.
This educational Expert Exchange features several relevant debates, with primary topics cultivated from top issues focused on evolving management strategies and recent clinical trial findings. Expert faculty will also facilitate case-based discussions centered on prominent clinical questions related to immune checkpoint inhibitor (ICI) treatment, some of which include: how to select appropriate treatment for a given patient, how best to sequence ICIs with other therapies, how to incorporate combination immunotherapies, the appropriate duration of treatment, and how to stop/restart immunotherapy if interrupted by immune-related adverse events. This dynamic and engaging format will not only provide learners with cutting-edge data and expert opinions, but will also offer an interactive, case-based opportunity for program participants to personally navigate emerging challenges of ICI management in bladder cancer.
This activity is designed to meet the educational needs of urologists and urologic oncologists who diagnose and manage urothelial cancer.
Upon completion of this activity, participants will be able to:
Review current status of checkpoint inhibitor use in urothelial bladder cancer at various stages of disease presentation and progression.
Explore the role of sequential therapy and multimodal and/or combination regimens involving checkpoint inhibitors.
Anticipate and appropriately manage adverse events that may occur in the use of checkpoint inhibitors in the patient with bladder cancer.
Conflict Of Interest Disclosure Policy
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest: research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Arjun V. Balar, MD Director, Genitourinary Medical Oncology Program NYU Langone Perlmutter Cancer Center New York, New York
Dr. Balar has disclosed that he is a consultant for AstraZeneca, Genentech, Merck, Pfizer, and Roche. He also receives grant/research support from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck.
Robert Dreicer, MD, MS, MACP, FASCO Associate Director for Clinical Research Deputy Director, University of Virginia Cancer Center Section Head, Medical Oncology Co-Director, Paul Mellon Urologic Cancer Institute Professor of Medicine and Urology University of Virginia School of Medicine Charlottesville, Virginia
Dr. Dreicer has disclosed that he is a consultant for Astellas, AstraZeneca, Eisai, Janssen, and Pfizer. He also receives grant/research support from Janssen, Merck, Novartis, and Seattle Genetics.
Ashish M. Kamat, MD, MBBS, FACS Professor of Urologic Oncology Wayne B. Duddlesten Professor of Cancer Research President, International Bladder Cancer Group (IBCG) University of Texas MD Anderson Cancer Center Houston, Texas
Dr. Kamat has disclosed that he is a consultant for Abbott Molecular, Arquer, Asieris, AstraZeneca, BioClin Therapeutics, Bristol-Myers Squibb, Cepheid, Cold Genesys, Eisai, Ferring, Imagin, MDxHealth, Medac, Merck, Pfizer, Photocure, Theralase, and US Biotest. He also receives grant/research support from Bristol-Myers Squibb, Merck, and Photocure.
Neal D. Shore, MD, FACS Director, CPI, Carolina Urologic Research Center Atlantic Urology Clinics Myrtle Beach, South Carolina
Dr. Shore has disclosed that he is a consultant and receives grant/research support from Abbvie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Color Genomics, Dendreon, Ferring, Genentech, Genomic Health, Genzyme, Innovia, Invitae, Janssen, Merck, Myriad, Nymox, Panacea, Pfizer, Roche, Sanofi, and Tolmar.
Planners and Reviewers Disclosures
Planners Joan B. Fowler, PharmD, BCPP, has no relevant financial relationships to disclose in relation to the content of this activity.
Bryan C. Taylor, PharmD, has no relevant financial relationships to disclose in relation to the content of this activity.
Peer Reviewer Bishoy Morris Faltas, MD (Weill Cornell Medicine, New York), has no relevant financial relationships to disclose in relation to the content of this activity.
AMA PRA Category 1 Credit(s)TM
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM . Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
It is the policy of CEC to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.
Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the learner is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to prescribing, dispensing, or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CEC for any product or manufacturer identified.
To obtain credit, a score of 75% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact: Creative Educational Concepts at email@example.com.